A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Sep 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

12 Sep 2023 Results of a post-hoc pooled analysis from two clinical studies (NCT02630459 and NCT03812224) assessing efficacy of erenumab in Japanese patients with low-frequency episodic migraine versus those with high-frequency episodic migraine and chronic migraine published in the Neurology and Therapy
13 Oct 2022 Results of post-hoc analysis of 4 studies (NCT02456740, NCT02066415, NCT02630459, and NCT03812224) assessing consistency of erenumab effect throughout the monthly treatment cycle, published in the Headache.
23 Jun 2021 Results presented in an Amgen Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com